Provided by Tiger Trade Technology Pte. Ltd.

Biohaven Pharmaceutical Holding Co Ltd.

16.95
+2.5717.87%
Post-market: 17.000.0500+0.29%16:50 EDT
Volume:15.72M
Turnover:256.31M
Market Cap:2.55B
PE:-3.78
High:18.24
Open:14.24
Low:13.00
Close:14.38
52wk High:18.57
52wk Low:7.48
Shares:150.42M
Float Shares:117.99M
Volume Ratio:6.11
T/O Rate:13.32%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.4800
EPS(LYR):-6.8648
ROE:-799.46%
ROA:-71.98%
PB:208.60
PE(LYR):-2.47

Loading ...

Update: Biohaven Shares Rise After Epilepsy Drug Licensing Deal

MT Newswires Live
·
2 hours ago

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Gossamer Bio (GOSS) and Biohaven Ltd. (BHVN)

TIPRANKS
·
2 hours ago

H.C. Wainwright says Biohaven license agreement buys time, ‘not a solution’

TIPRANKS
·
3 hours ago

Biohaven rises 10.8%

TIPRANKS
·
4 hours ago

Biohaven Shares Gain 5% on SK Biopharma Epilepsy Licensing Deal Worth up to $795 Million

THOMSON REUTERS
·
Yesterday

U.S. Stocks on the MOVE-Semtech, Donaldson, Meta

Reuters
·
Yesterday

Delaware Court Enters USD 4 Million Judgment for Biohaven, Yale in Trade Secret Case Against RA Capital, Avilar

Reuters
·
Yesterday

Biohaven to receive $400M in SK Biopharmaceuticals licensing, collaboration pact

TIPRANKS
·
Yesterday

Biohaven Licenses Kv7 Epilepsy Drug Platform to SK Biopharmaceuticals in Deal Worth up to USD 795 Million

Reuters
·
Yesterday

Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy

THOMSON REUTERS
·
Yesterday

Biohaven - SK Biopharmaceuticals to Pay up to $795 Mln Plus Tiered U.S. Royalties to Biohaven

THOMSON REUTERS
·
Yesterday

Biohaven - to Receive $400 Mln Cash, Including $350 Mln at Closing and $50 Mln in 2027

THOMSON REUTERS
·
Yesterday

Biohaven - Eligible for $150 Mln in Development and Regulatory Milestones Plus Global Royalties

THOMSON REUTERS
·
Yesterday

Biohaven Receives Favorable Ruling in the Trade Secret Misappropriation Lawsuit

MT Newswires Live
·
Yesterday

Biohaven - Federal Court Confirms Ra Capital and Avilar Therapeutics "Misappropriated" Yale Trade Secret

THOMSON REUTERS
·
Yesterday

Biohaven - U.S. District Court Awards $4 Mln to Biohaven and Yale in Trade Secret Case

THOMSON REUTERS
·
Yesterday

Biohaven Files Form 3 Initial Beneficial Ownership Statement for Director John Yetimoglu

Reuters
·
Aug 15

Biohaven Supported by Multiple Pipeline Catalysts, Cash Runway Into 2027, RBC Says

MT Newswires Live
·
Aug 11

RBC Adjusts Price Target on Biohaven to $23 From $22, Maintains Outperform Speculative Risk Rating

MT Newswires Live
·
Aug 11

Bank of America Securities Reaffirms Their Buy Rating on Biohaven Ltd. (BHVN)

TIPRANKS
·
Aug 11